News | PET-CT | November 01, 2016

Optical and PET/CT Probes Detect Early Signs of Atherosclerosis

The activity-based probes image the vascular inflammation involved in plaque formation

PET/CT, atherosclerotic plaque detection, Stanford University

Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries.  PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.

November 1, 2016 — Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission tomography (PET)/computed tomography (CT) activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of The Journal of Nuclear Medicine.

Atherosclerosis is largely an asymptomatic disease where plaques develop over decades and symptoms do not appear until greater than 70 percent of a vessel is occluded. This results in significant risk of severe cardiovascular events such as stroke or myocardial infractions, highlighting the need for early, non-invasive diagnosis of the disease.

Matthew Bogyo, Ph.D., one of the lead authors of the study explained, “This collaborative study with Zhen Cheng, Ph.D., and Michael McConnell, M.D., provides evidence that these probes have potential benefits for non-invasive imaging of atherosclerotic plaque inflammation, potentially leading to the application of this probe in the clinic to help identify patients at high risk of developing premature atherosclerosis.”

Macrophages are cellular mediators of vascular inflammation and are involved in the formation of atherosclerotic plaques. These immune cells secrete proteases such as matrix metalloproteinases and cathepsins that contribute to disease formation and progression. In this study, activity-based probes (ABPs) targeting cysteine cathepsins were used in mouse models of atherosclerosis to non-invasively image activated macrophage populations using both optical and PET/CT methods. The probes were also used to topically label human carotid plaques, demonstrating similar specific labeling of activated macrophage populations. 

The study demonstrates that ABPs targeting the cysteine cathepsins offer a rapid, non-invasive way to image atherosclerotic disease progression and plaque vulnerability.

Bogyo noted, “What’s novel about this is the fact that these probes provide accurate detection of lesions undergoing high levels of inflammatory activity and extracellular matrix remodeling. They not only enable early disease detection, they can provide real-time monitoring of therapeutic responses and clinical drug efficacy.”

He sees broader uses for the probes in the future. “The probes show efficacy in a variety of imaging modalities, including fluorescence, PET/CT, and topical application of the probe to fresh frozen murine and human tissue sections. These tools further demonstrate that the future of molecular imaging and nuclear medicine will be focused on agents that allow specific targeting of disease-associated proteins or markers that allow monitoring of disease onset, progress and response to therapeutic agents,” he said.

For more information: www.jnm.snmjournals.org

Related Content

Siemens Healthineers, Compressed Sensing technology, MRI, FDA approval, RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | February 21, 2017
Siemens Healthineers announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Compressed...
News | Radiopharmaceuticals and Tracers | February 16, 2017
Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the...
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | Cardiac Imaging | February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017
Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer...
PET/CT, primary and metastatic prostate cancer, Journal of Nuclear Medicine study, JNM

Ga-68-BBN PET/CT of a 64-year-old man newly diagnosed with prostate cancer by biopsy. Multiple bone metastasis lesions (arrows) were detected. Image courtesy of Jingjing Zhang, Peking Union Medical College, Beijing, China.

News | Prostate Cancer | February 02, 2017
In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first...
RSNA 2016, short-term sleep deprivation effects, heart function, clinical study, cardiac magnetic resonance, CMR strain analysis
News | Magnetic Resonance Imaging (MRI) | February 01, 2017
Too little sleep takes a toll on your heart, according to a new study presented at the 2016 annual meeting of the...
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Arterys, Cardiac MRI, cardiac MRI advances

An example of the Arterys blood flow imaging assessment software that can help automate cardiac MRI. 

Feature | RSNA 2016 | January 30, 2017 | Dave Fornell
Each year imaging system manufacturers use the Radiological Society of North America (RSNA) meeting at the end of the
Gamma Medica, LumaGEM molecular breast imaging system, MBI technology, Major Health Partners Indiana
News | Breast Imaging | January 26, 2017
Gamma Medica recently announced that through its collaboration with Ohio-based Alpha Imaging, Indiana-based Major...
News | PET Imaging | January 25, 2017
In work published this week in the Journal of Clinical Investigation (JCI), a team led by Jacob Hooker at Harvard...
Overlay Init